Cover Image
Read Now

Immune checkpoint inhibitors for classical Hodgkin lymphoma in brentuximab vedotin-naïve patients a review of clinical effectiveness, cost-effectiveness, and guidelines

There was no primary evidence regarding the clinical effectiveness or cost-effectiveness of immune checkpoint inhibitors for brentuximab vedotin-naïve adults with relapsed or refractory classical Hodgkin lymphoma, irrespective of eligibility for or prior history of autologous stem cell transplantat...

Full description

Bibliographic Details
Main Authors: Williams, D., Gray, Casey (Author), Picheca, Lory (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH June 21, 2019, 2019
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Adult
Nivolumab / Therapeutic Use
Cost-benefit Analysis
Hodgkin Disease / Drug Therapy
Hodgkin Disease / Immunology
Cell Cycle Checkpoints / Drug Effects
Treatment Outcome
Antibodies, Monoclonal, Humanized / Therapeutic Use
Guidelines As Topic
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:There was no primary evidence regarding the clinical effectiveness or cost-effectiveness of immune checkpoint inhibitors for brentuximab vedotin-naïve adults with relapsed or refractory classical Hodgkin lymphoma, irrespective of eligibility for or prior history of autologous stem cell transplantation
Physical Description:1 PDF file (16 pages) illustration

Similar Items